Recommendation of the President – Tecartus (brexucabtagene autoleucel)
On 25 July 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 101/2025 on the inclusion of the medicinal product Tecartus (brexucabtagene autoleucel) in the B.12.FM drug program. Treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85)